Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium
- W. Vincken, J. V. van Noord, +4 authors P. Cornelissen
- European Respiratory Journal
- 1 February 2002
Tiotropium was effective in improving dyspnoea, exacerbations, health-related quality of life and lung function in patients with chronic obstructive pulmonary disease, and exceeds the benefits seen with ipratropium. Expand
A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol.
Tiotropium once daily produces superior bronchodilation, improvements in dyspnea, and proportion of patients achieving meaningful changes in HRQoL compared to twice-daily salmeterol in patients with COPD. Expand
Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial
Once-daily NVA237 was safe and well tolerated and provided rapid, sustained improvements in lung function, improvements in dyspnoea, and health-related quality of life, and reduced the risk of exacerbations and the use of rescue medication. Expand
Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease
Tiotropium produced sustained bronchodilation throughout the 24 hour day without necessarily abolishing circadian variation in airway calibre. Expand
Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium.
- J. V. van Noord, D. D. de Munck, T. Bantje, W. Hop, M. Akveld, A. Bommer
- The European respiratory journal
- 1 May 2000
In patients with severe stable chronic obstructive pulmonary disease, long-term treatment with either salmeterol alone orSalmeterol plus ipratropium is safe and effective and there was added benefit from the combination therapy in terms of improvement in airways obstruction, but not for improvement in symptom control or need for rescue salbutamol. Expand
Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial.
- H. Kerstjens, B. Disse, +5 authors J. V. van Noord
- The Journal of allergy and clinical immunology
- 1 August 2011
The addition of once-daily tiotropium to asthma treatment, including a high-dose inhaled corticosteroid plus a long-acting β₂-agonist, significantly improves lung function over 24 hours in patients with inadequately controlled, severe, persistent asthma. Expand
Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD.
In the treatment of COPD, there is benefit from adding formoterol once or twice daily to tiotropium once daily in terms of improvement in airflow obstruction, resting hyperinflation, and the use of rescue salbutamol. Expand
The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
- J. V. van Noord, P. Cornelissen, J. Aumann, J. Platz, A. Mueller, C. Fogarty
- Respiratory medicine
Tiotropium 5 microg Respimat SMI is comparable with tiotropia 18 microg HandiHaler in terms of efficacy, pharmacokinetics and safety and is an effective alternative, multi-dose delivery device for tiotroropium. Expand
Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma
The addition of montelukast to inhaled budesonide is an effective and well tolerated alternative to doubling the dose of inhaled Budesonide in adult asthma patients experiencing symptoms and inadequate control on budesonid alone. Expand
Reduced E-cadherin expression is associated with increased lymph node metastasis and unfavorable prognosis in non-small cell lung cancer.
- M. Sulzer, M. Leers, J. V. van Noord, E. Bollen, P. Theunissen
- American journal of respiratory and critical care…
- 1 April 1998
Clinical evidence that reduced E-cadherin expression is associated with tumor dedifferentiation, increased lymphogenous metastasis and poor survival is provided and it seems that E- cadher in expression might be an important prognostic factor in NSCLC. Expand